N/A
Completed N=11
Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers
Healthy
Source: ClinicalTrials.gov NCT01204255 ↗
Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Aug 2011
Primary outcomePrimary: Lorazepam, Diphenyhydramine, Haloperidol Absorption — 0; .08; 0 ng/ml
Summary
RATIONALE: Lorazepam, diphenhydramine hydrochloride, and haloperidol gel, when absorbed into the skin, may be an effective treatment for nausea and vomiting.PURPOSE: This clinical trial studies lorazepam, diphenhydramine hydrochloride, and haloperidol gel in healthy volunteers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Lorazepam, Diphenyhydramine, Haloperidol Absorption |
0; .08; 0 | — |
| SECONDARY Side Effects |
— | — |
Eligibility Criteria
Inclusion Criteria
- Completed a medical screening questionnaire
- English speaking
- No allergies to the drugs
- Able to complete the forms
- If a woman of childbearing age, agree to use contraception
Exclusion Criteria
- History of substance abuse, psychiatric disorder, acquired brain injury, the possibility of pregnancy (not using birth control, and of child bearing age)
- Use of any medication that would contraindicate benzodiazepine administration
- Pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT01204255). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.